This is definitely a list few, if any, companies want to be on. Source: BioSpace

The cash will support expansion in translational informatics, clinical trials, and broadened use of biomedical data. Source: BioSpace

A look at two biopharma companies that fall into this category that investors should check out. Source: BioSpace

Centrexion closed on a Series D financing worth $67M to develop its knee osteoarthritis drug in Phase III. Source: BioSpace

Three biotech companies want to start out the new year with a new start. Source: BioSpace

At closing of the agreement, $75 million in aggregate principal amount of the Senior Secured Notes were issued. Source: BioSpace

From around 2014 through 2016, Valeant seemingly had a crisis story per week, ranging from insider trading to channel stuffing Source: BioSpace

The company's sales department will take the brunt of the layoffs, losing 235 jobs. Source: BioSpace

Celgene announced back in October that it was discontinuing its GED-0301 program for Crohn's disease and now that decision is costing the company $411M. Source: BioSpace

The J.P. Morgan Healthcare Conference is held every year in early January, and this year it will be Jan. 8-11 in San Francisco, as usual. Source: BioSpace